Eli Lilly Overview

  • Year Founded
  • 1876

Year Founded

  • Status
  • Public

  • Employees
  • 47,000

Employees

  • Stock Symbol
  • LLY

Stock Symbol

  • Investments
  • 194

  • Share Price
  • $771.71
  • (As of Friday Closing)

Eli Lilly General Information

Description

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Contact Information

Website
www.lilly.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States
+1 (317)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NYS
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States
+1 (317)

Eli Lilly Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eli Lilly Stock Performance

As of 18-Jul-2025, Eli Lilly’s stock price is $771.71. Its current market cap is $693B with 898M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$771.71 $761.50 $677.09 - $972.53 $693B 898M 3.91M $12.34

Eli Lilly Financials Summary

As of 31-Mar-2025, Eli Lilly has a trailing 12-month revenue of $49B.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 771,958,720 721,953,716 571,131,575 360,855,183
Revenue 49,003,200 45,042,700 34,124,100 28,541,400
EBITDA 16,096,200 15,052,400 8,394,200 8,597,700
Net Income 11,106,400 10,590,000 5,240,400 6,244,800
Total Assets 89,388,800 78,714,900 64,006,300 49,489,800
Total Debt 38,515,900 33,644,200 25,225,300 16,238,600
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eli Lilly Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eli Lilly‘s full profile, request access.

Request a free trial

Eli Lilly Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products inc
Pharmaceuticals
Indianapolis, IN
47,000 As of 2024

Thousand Oaks, CA
 

Princeton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eli Lilly Competitors (25)

One of Eli Lilly’s 25 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA
Bristol-Myers Squibb Corporation Princeton, NJ
AbbVie Corporation North Chicago, IL
Pfizer (Pharmaceuticals) Corporation New York, NY
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 25 competitors. Get the full list »

Eli Lilly Patents

  • 33,014

    Total Documents Applications and Grants

  • Total Patents Families

  • 9,025

    Granted

  • 2,647

    Pending

  • Expiring in next 12 mo

Eli Lilly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250197413-A1 Rxfp1 receptor agonists Pending 15-Dec-2023
US-20250205352-A1 Compositions and methods for modulating nav1.8 Pending 13-Dec-2023
US-20250197493-A1 Lag-3 agonist antibodies Pending 13-Dec-2023
US-20250163119-A1 Compounds for the treatment of diabetes or obesity Pending 17-Nov-2023
US-D1084128-S1 Label Active 06-Nov-2023
To view Eli Lilly’s complete patent history, request access »

Eli Lilly Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eli Lilly Investments & Acquisitions (194)

Eli Lilly’s most recent deal was a Seed Round with Laverock Therapeutics for . The deal was made on 30-Jun-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Laverock Therapeutics 30-Jun-2025 Seed Round Biotechnology
Verve Therapeutics 17-Jun-2025 Merger/Acquisition Drug Discovery
Signify Bio 06-Jun-2025 Early Stage VC Biotechnology
Camurus (Worldwide Rights in Lund, Sweden) 03-Jun-2025 Corporate Asset Purchase Buildings and Property
SiteOne Therapeutics 27-May-2025 Merger/Acquisition Drug Discovery
You’re viewing 5 of 194 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Eli Lilly ESG

Risk Overview

Risk Rating

Updated July, 01, 2025

23.36 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,697

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 420

Rank

Percentile

To view Eli Lilly’s complete esg history, request access »

Eli Lilly Exits (46)

Eli Lilly’s most recent exit was on 01-Feb-2024 from BioAge Labs. The exit was categorized as with 15 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
BioAge Labs 01-Feb-2024 Completed
  • 15 buyers
Foghorn Therapeutics 13-Dec-2021 Completed
Cedilla Therapeutics 25-Oct-2021 Completed
  • 9 buyers
Acrivon Therapeutics 29-Jun-2021 Completed
  • 4 buyers
DTx Pharma 21-Mar-2021 Later Stage VC Completed
  • 18 buyers
You’re viewing 5 of 46 exits. Get the full list »

Eli Lilly Affiliates

Subsidiaries (13)

Name Industry Location Year Founded
Versanis Bio Oakland, CA 2020
Prevail Therapeutics New York, NY 2017
Akouos Boston, MA 2016
Aparito Wrexham, United Kingdom 2014
Protomer Technologies Pasadena, CA 2014
You’re viewing 5 of 13 affiliates. Get the full list.  »

Eli Lilly FAQs

  • When was Eli Lilly founded?

    Eli Lilly was founded in 1876.

  • Where is Eli Lilly headquartered?

    Eli Lilly is headquartered in Indianapolis, IN.

  • What is the size of Eli Lilly?

    Eli Lilly has 47,000 total employees.

  • What industry is Eli Lilly in?

    Eli Lilly’s primary industry is Pharmaceuticals.

  • Is Eli Lilly a private or public company?

    Eli Lilly is a Public company.

  • What is Eli Lilly’s stock symbol?

    The ticker symbol for Eli Lilly is LLY.

  • What is the current stock price of Eli Lilly?

    As of 18-Jul-2025 the stock price of Eli Lilly is $771.71.

  • What is the current market cap of Eli Lilly?

    The current market capitalization of Eli Lilly is $693B.

  • What is Eli Lilly’s current revenue?

    The trailing twelve month revenue for Eli Lilly is $49B.

  • Who are Eli Lilly’s competitors?

    Amgen, Bristol-Myers Squibb, AbbVie, Pfizer (Pharmaceuticals), and Merck & Co. are some of the 25 competitors of Eli Lilly.

  • What is Eli Lilly’s annual earnings per share (EPS)?

    Eli Lilly’s EPS for 12 months was $12.34.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »